Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


25.11.2019

11 Ann Thorac Surg
2 BMC Cancer
1 Cancer Chemother Pharmacol
1 Chest
1 Clin Cancer Res
1 Clin Nucl Med
1 Eur J Cardiothorac Surg
1 Eur Respir J
2 Hum Pathol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Thorac Cardiovasc Surg
1 J Thorac Oncol
5 Lung Cancer
2 N Engl J Med
1 Oncogene
2 Oncol Rep
1 Oncologist
2 PLoS One
2 Semin Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. RICE JD, Heidel J, Trivedi JR, van Berkel VH, et al
    Optimal Surgical Timing after Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2019 Nov 19. pii: S0003-4975(19)31705.
    PubMed     Text format     Abstract available

  2. LENOIR B, Bruner ET, Denlinger CE, Gibney BC, et al
    Extramedullary Plasmacytoma of the Right Main Bronchus.
    Ann Thorac Surg. 2019;108:e119-e120.
    PubMed     Text format     Abstract available

  3. BROWN K, Homer R, Baine M, Blasberg JD, et al
    Short Tandem Repeats Define a Gestational Origin for Metastatic Choriocarcinoma.
    Ann Thorac Surg. 2019;108:e115-e117.
    PubMed     Text format     Abstract available

  4. PENG Q, Zhang L, Ren Y, He W, et al
    Reconstruction of Long Noncircumferential Tracheal or Carinal Resections With Bronchial Flaps.
    Ann Thorac Surg. 2019;108:417-423.
    PubMed     Text format     Abstract available

  5. YAJIMA T, Shimizu K, Mogi A, Ibe T, et al
    Pulmonary Artery Compression Facilitates Intersegmental Border Visualization.
    Ann Thorac Surg. 2019;108:e141-e143.
    PubMed     Text format     Abstract available

  6. UEDA K, Haruki T, Murakami J, Tanaka T, et al
    No Drain After Thoracoscopic Major Lung Resection for Cancer Helps Preserve the Physical Function.
    Ann Thorac Surg. 2019;108:399-404.
    PubMed     Text format     Abstract available

  7. GERACI TC, Ferrari-Light D, Kent A, Michaud G, et al
    Technique, Outcomes With Navigational Bronchoscopy Using Indocyanine Green for Robotic Segmentectomy.
    Ann Thorac Surg. 2019;108:363-369.
    PubMed     Text format     Abstract available

  8. KIM TH, Buonocore D, Petre EN, Durack JC, et al
    Utility of Core Biopsy Specimen to Identify Histologic Subtype and Predict Outcome for Lung Adenocarcinoma.
    Ann Thorac Surg. 2019;108:392-398.
    PubMed     Text format     Abstract available

  9. SAMEJIMA J, Ito H, Nakayama H, Nagashima T, et al
    Which Window Setting Is Best for Estimating Pathologic Invasive Size and Invasiveness?
    Ann Thorac Surg. 2019;108:384-391.
    PubMed     Text format     Abstract available

  10. RAMAN V, Jawitz OK, Yang CJ, Tong BC, et al
    Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis.
    Ann Thorac Surg. 2019;108:377-383.
    PubMed     Text format     Abstract available

  11. TURNER SR, Nasir BS, Lai H, Yasufuku K, et al
    Development and Pilot Testing of an Assessment Tool for Performance of Invasive Mediastinal Staging.
    Ann Thorac Surg. 2019;108:590-596.
    PubMed     Text format     Abstract available


    BMC Cancer

  12. MIURA S, Naito T, Mitsunaga S, Omae K, et al
    A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.
    BMC Cancer. 2019;19:528.
    PubMed     Text format     Abstract available

  13. HANSEN MS, Licaj I, Braaten T, Langhammer A, et al
    Smoking related lung cancer mortality by education and sex in Norway.
    BMC Cancer. 2019;19:1132.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  14. SCHETT A, Rothschild SI, Curioni-Fontecedro A, Krahenbuhl S, et al
    Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Cancer Chemother Pharmacol. 2019 Nov 19. pii: 10.1007/s00280-019-03993.
    PubMed     Text format     Abstract available


    Chest

  15. SAINZ ZUNIGA PV, Vakil E, Molina S, Bassett RL Jr, et al
    Sensitivity of Radial Endobronchial Ultrasound Guided Bronchoscopy for Lung Cancer in Patients with Peripheral Pulmonary Lesions: An Updated Meta-Analysis.
    Chest. 2019 Nov 15. pii: S0012-3692(19)34213-8. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  16. ZHANG J, Ji Z, Caushi JX, El Asmar M, et al
    Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 21. pii: 1078-0432.CCR-19-2931.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  17. HOD N, Levin D, Anconina R, Taragin BH, et al
    68Ga-DOTATATE PET/CT in Focal Fatty Sparing of the Liver.
    Clin Nucl Med. 2019 Jul 24. doi: 10.1097/RLU.0000000000002746.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  18. SETOJIMA Y, Shimada Y, Tanaka T, Shigefuku S, et al
    Prognostic impact of solid-part tumour volume doubling time in patients with radiological part-solid or solid lung cancer.
    Eur J Cardiothorac Surg. 2019 Nov 20. pii: 5634181. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur Respir J

  19. SUISSA S, Dell'Aniello S, Gonzalez AV, Ernst P, et al
    Inhaled corticosteroid use and the incidence of lung cancer in COPD.
    Eur Respir J. 2019 Nov 19. pii: 13993003.01720-2019.
    PubMed     Text format     Abstract available


    Hum Pathol

  20. HUNG YP, Hunninghake GM, Miller ER, Putman R, et al
    Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions.
    Hum Pathol. 2019;86:93-101.
    PubMed     Text format     Abstract available

  21. CHAPEL DB, Stewart R, Furtado LV, Husain AN, et al
    Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Hum Pathol. 2019;87:11-17.
    PubMed     Text format     Abstract available


    Int J Cancer

  22. BOECKX B, Bahadur Shahi R, Smeets D, De Brakeleer S, et al
    The genomic landscape of non-small cell lung carcinoma in never smokers.
    Int J Cancer. 2019 Nov 19. doi: 10.1002/ijc.32797.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  23. QIN A, Rengan R, Lee S, Santana-Davila R, et al
    A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Nov 19. pii: S0360-3016(19)34007.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  24. YANG Z, Xu J, Li R, Gao Y, et al
    PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
    J Cancer Res Clin Oncol. 2019;145:3055-3065.
    PubMed     Text format     Abstract available


    J Clin Oncol

  25. MAZIERES J, Kowalski D, Luft A, Vicente D, et al
    Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Nov 21:JCO1901348. doi: 10.1200/JCO.19.01348.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  26. NWOGU CE
    Commentary: Are two local therapies better than one for early-stage small cell lung cancer?
    J Thorac Cardiovasc Surg. 2019;158:1679.
    PubMed     Text format    


    J Thorac Oncol

  27. HUBER RM, Hansen KH, Paz-Ares Rodriguez L, West HL, et al
    Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
    J Thorac Oncol. 2019 Nov 19. pii: S1556-0864(19)33645.
    PubMed     Text format     Abstract available


    Lung Cancer

  28. GERBER DE, Camidge DR, Morgensztern D, Cetnar J, et al
    Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
    Lung Cancer. 2019;139:60-67.
    PubMed     Text format     Abstract available

  29. TSUKITA Y, Inoue A, Sugawara S, Kuyama S, et al
    Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
    Lung Cancer. 2019;139:89-93.
    PubMed     Text format     Abstract available

  30. MATSUMOTO Y, Sawa K, Fukui M, Oyanagi J, et al
    Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2019;139:80-88.
    PubMed     Text format     Abstract available

  31. CONG M, Feng H, Ren JL, Xu Q, et al
    Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer.
    Lung Cancer. 2019;139:73-79.
    PubMed     Text format     Abstract available

  32. DREVET G, Duruisseaux M, Maury JM, Benjamin R, et al
    Lung cancer surgical treatment after solid organ transplantation: A single center 30-year experience.
    Lung Cancer. 2019;139:55-59.
    PubMed     Text format     Abstract available


    N Engl J Med

  33. MACKAY DF, Russell ER, Stewart K, MacLean JA, et al
    Neurodegenerative Disease Mortality among Former Professional Soccer Players.
    N Engl J Med. 2019;381:1801-1808.
    PubMed     Text format     Abstract available

  34. MIYASHIRO D, Sanches JA
    Velvety Palms.
    N Engl J Med. 2019;381:e35.
    PubMed     Text format    


    Oncogene

  35. JIN Y, Bao H, Le X, Fan X, et al
    Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
    Oncogene. 2019 Nov 21. pii: 10.1038/s41388-019-1104.
    PubMed     Text format     Abstract available


    Oncol Rep

  36. CHANG WC, Kim HK, Shin BK
    Clinicopathological features and diagnostic methods of ALK fusionpositive nonsmall cell lung cancer in Korea.
    Oncol Rep. 2019 Nov 4. doi: 10.3892/or.2019.7399.
    PubMed     Text format     Abstract available

  37. ZHANG J, Li D, Zhang Y, Ding Z, et al
    Integrative analysis of mRNA and miRNA expression profiles reveals seven potential diagnostic biomarkers for nonsmall cell lung cancer.
    Oncol Rep. 2019 Nov 13. doi: 10.3892/or.2019.7407.
    PubMed     Text format     Abstract available


    Oncologist

  38. AKAMATSU H, Murakami E, Oyanagi J, Shibaki R, et al
    Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2019 Nov 19. pii: theoncologist.2019-0299.
    PubMed     Text format     Abstract available


    PLoS One

  39. KIM I, Eom JS, Kim AR, Lee CH, et al
    Molecular analysis of small tissue samples obtained via transbronchial lung biopsy using radial probe endobronchial ultrasound.
    PLoS One. 2019;14:e0212672.
    PubMed     Text format     Abstract available

  40. HAYASHI K, Motoishi M, Sawai S, Horimoto K, et al
    Postoperative delirium after lung resection for primary lung cancer: Risk factors, risk scoring system, and prognosis.
    PLoS One. 2019;14:e0223917.
    PubMed     Text format     Abstract available


    Semin Oncol

  41. TSAO A, Nakano T, Nowak AK, Popat S, et al
    Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Semin Oncol. 2019;46:145-154.
    PubMed     Text format     Abstract available

  42. HOPKINS AM, Kichenadasse G, McKinnon RA, Rowland A, et al
    Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
    Semin Oncol. 2019 Nov 6. pii: S0093-7754(19)30127.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: